Medindia
Why Register as Premium Member if you have Diabetes? Click Here
Medindia » Cancer News

Vaccine and Antibody Ignite Immune Response in Pancreatic Cancer

by Colleen Fleiss on July 18, 2023 at 11:39 PM
Listen to this News

Administering a triple combination immunotherapy treatment to patients with operable pancreatic cancers, consisting of the pancreatic cancer vaccine GVAX, the immune checkpoint therapy nivolumab, and urelemab, an anti-CD137 agonist antibody treatment, has been deemed safe ().

Advancing Immunotherapies for Pancreatic Cancer

This study, led by researchers at the Johns Hopkins Kimmel Cancer Center, the Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins University School of Medicine, is the latest from an ongoing platform trial formed in 2015 to study immunotherapy treatments before surgery (neoadjuvant) and after surgery (adjuvant) for patients with pancreatic cancer. This format enables researchers to use data generated by the trial to advance development of immunotherapies for pancreatic cancer within the same study.


In this most recent part of the trial, 10 participants received the combination treatment. The median disease-free survival - the amount of time after treatment during which no cancer is found - was 33.51 months, and the median overall survival - time to death - was 35.5 months. These were higher than found in previous arms of the trial that tested the pancreatic cancer vaccine alone and in combination with nivolumab, but because of the small number of patients, the results did not have statistical significance.

‘Pancreatic cancer benefits from a combination of treatments, including vaccine GVAX, immune checkpoint therapy, and an anti-CD137 agonist antibody. #pancreaticcancer #pancreaticcancertreatment’

The tumor specimens studied in the recent arm also had much higher amounts of cancer-killing immune cells than specimens from patients given only the vaccine or the vaccine plus nivolumab.

The results suggest that this therapy combination warrants further study in a larger clinical trial, says senior study author Lei Zheng, M.D., Ph.D., co-director of the Pancreatic Cancer Precision Medicine Center of Excellence and professor of oncology at the Johns Hopkins University School of Medicine.

The platform trial has two purposes regarding pancreatic cancer treatments given during the two-week "window of opportunity" prior to surgery, Zheng says. First, it allows the immunotherapies to teach the patient's immune cells how to respond to tumors, so they can continue surveillance later if the cancer recurs. Second, it enables investigators to see, by evaluating the tumors removed during surgery, how well the tumors respond to the treatment. A fourth arm of the trial, studying anti-interleukin-8 neutrophil-blocking antibodies in pancreatic tumors, is ongoing.

Reference:

  1. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma - (https:www.ncbi.nlm.nih.gov/pmc/articles/PMC10281953/)
Source: Eurekalert

View Non AMP Site | Back to top ↑